How to setup a successful transplant program for hemoglobinopathies in developing countries: The Cure2Children approach
- PMID: 32201151
- DOI: 10.1016/j.hemonc.2019.12.010
How to setup a successful transplant program for hemoglobinopathies in developing countries: The Cure2Children approach
Abstract
Hematopoietic stem cell transplantation (HSCT) remains the only established definitive cure for severe hemoglobinopathies, such as sickle cell disease (SCD) and thalassemia-the most prevalent life-threatening non-communicable disease of childhood globally. HSCT can not only cure over 85% of children with a compatible sibling but also restore normal health-related quality of life in most cases who do not have major irreversible organ damage at transplant. In low- and middle-income countries (LMICs), particularly in sub-Saharan Africa, SCD carrier rate can be up to 30% and 1% of live births have SCD. Relatively simple and inexpensive measures such as newborn screening, early diagnosis, caregiver education, and timely institution of anti-pneumococcal prophylaxis and hydroxyurea therapy can substantially reduce SCD-related mortality and morbidity. Improved prevention and early care should proceed in parallel with the development of transplant services and hope for cure. Cure2Children, an Italian NGO, has supported the startup of several bone marrow transplantation programs in LMICs where over 500 transplants have been performed over the last 10 years, with outcomes not substantially different from high-income countries but at a fraction of the cost. This report summarizes this experience and suggests some strategies to set up new HSCT units.
Keywords: Africa; Hematopoietic stem cell transplantation; India; International Medicine; Sickle cell disease; Thalassemia.
Copyright © 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.Biol Blood Marrow Transplant. 2016 Jun;22(6):1043-1048. doi: 10.1016/j.bbmt.2016.03.003. Epub 2016 Mar 23. Biol Blood Marrow Transplant. 2016. PMID: 27016193
-
Allogeneic cellular gene therapy for hemoglobinopathies.Hematol Oncol Clin North Am. 2010 Dec;24(6):1145-63. doi: 10.1016/j.hoc.2010.08.004. Epub 2010 Sep 29. Hematol Oncol Clin North Am. 2010. PMID: 21075285 Review.
-
Combined umbilical cord blood and bone marrow from HLA-identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies.Pediatr Blood Cancer. 2014 Sep;61(9):1690-4. doi: 10.1002/pbc.25085. Epub 2014 May 7. Pediatr Blood Cancer. 2014. PMID: 24803091
-
A Hematopoietic Stem Cell Transplantation Startup in Iraqi Kurdistan: Results in Thalassemia Patients and Analysis of the Methodology.Transplant Cell Ther. 2023 May;29(5):329.e1-329.e7. doi: 10.1016/j.jtct.2023.01.018. Epub 2023 Jan 20. Transplant Cell Ther. 2023. PMID: 36690277
-
Hematopoietic Stem Cell Transplantation in Patients with Hemoglobinopathies.Hemoglobin. 2020 Nov;44(6):377-384. doi: 10.1080/03630269.2020.1832516. Epub 2020 Oct 13. Hemoglobin. 2020. PMID: 33050763 Review.
Cited by
-
Why and How Should Ethiopia Establish a Stem Cell Transplant Service? A Review Article.Biologics. 2023 Mar 20;17:33-40. doi: 10.2147/BTT.S401289. eCollection 2023. Biologics. 2023. PMID: 36969332 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources